Introduction: Microscopic colitis (MC) is a major cause of chronic watery diarrhoea. The international incidence rates are variable. Currently, the exact disease course and predictive markers for disease activity remain unknown. Small retrospective studies point towards an intermittent or chronic course with low rates of spontaneous remission, but prospective studies are lacking. Therefore, the PRO-MC Collaboration, a European prospective registry for MC 1 , was initiated. Aims & Methods: Only incident cases of MC were eligible for inclusion. Patient characteristics and baseline data on pathology, disease activity, medical history, performed diagnostics and treatment strategies were registered. Patients will be followed prospectively at 3, 6, 12 months and then yearly. Results: By august 2017, 193 individuals were included, mean age 65 (AE14 (SD)) years, 69% females and 28% current smokers. In total, 87 had collagenous colitis (CC), 79 lymphocytic colitis (LC) and 27 incomplete MC (MCi). The mean time between endoscopy and baseline visit was 57 AE 82 days. Diarrhoea persisted for 46 months before diagnosis in 43%. Macroscopic abnormalities were present during index colonoscopy in 23%. At baseline visit, urgency was reported by 80%, nightly defecation by 46%, faecal incontinence and abdominal pain by 48%, and moderate to severe functional impairment by 52% of patients. Four out of 10 had bile acid diarrhoea by SeHCAT. At the baseline visit, 75% had active disease according to the Hjortswang criteria 2 . Treatment to induce clinical remission was initiated in 54% of patients, of which 94% were treated with budesonide. In 26% of patients no medical treatment was initiated. Patients scored 4-5 out of 10 on the Short Health Scale (SHS) items (symptom severity, interference with daily activity, worry about MC and general wellbeing). Three months later, 53% of 103 patients had disease activity, 33% urgency, 6% faecal incontinence, 8% nightly defecation, and 19% reported moderate to severe functional impairment. SHS scores improved to 2.5-3. After three months, 52% of patients were without treatment, 11% on induction therapy (in 83% with budesonide), 13% on maintenance therapy (29% budesonide, others with fibers, loperamide and/or colestyramine), 14% were tapering the dose (mainly budesonide, 93%) and 10% had treatment on demand. Oral budesonide was stopped due to absence or loss of response in 9% of treated patients. Conclusion: The PRO-MC Collaboration is accumulating incident cases of MC. Initial symptoms resemble those of previous single site cohort and confirm that disease activity causes major functional impairment. Follow-up data of this cohort will provide data on long-term prognosis and may help to identify predictive factors for disease activity and response to treatment in real life.
erant or refractory (IR) to TNF antagonists (aTNFs) are a difficult-to-treat population with an important unmet medical need. Accurate endoscopic assessments of drug efficacy for UC now rely on independent reading of endoscopic videos by expert readers blinded to patient information. Centrally read endoscopy has reduced placebo endoscopic remission rates in this population to as low as 0%-8%. 1, 2 HICKORY OLI evaluates the safety and efficacy of etrolizumab in patients IR to aTNFs. Aims & Methods: This study evaluates response to etrolizumab OLI via centrally read endoscopy, patient-reported outcomes, and inflammatory biomarkers in patients who are IR to aTNFs. All patients received etrolizumab 105 mg subcutaneously every 4 weeks in a 14-week induction period. Mayo subscores based on endoscopic score (ES), and patient-reported rectal bleeding (RB) and stool frequency (SF) were assessed at baseline (BL) and week 14. Clinical response: !3point and 30% reduction of Mayo Clinic score (MCS) from BL and !1-point decrease in RB or RB 1. Remission: MCS 2 with individual subscores 1 and RB ¼ 0. Endoscopic improvement: ES 1. RB remission: RB ¼ 0; SF remission: SF 1 with !1-point reduction from BL. The percentage declines from BL in RB and SF at week 14 were also calculated. Results: HICKORY OLI enrolled 130 aTNF-experienced patients with UC; 45% had previously failed 41 aTNF. BL disease activity included a mean MCS of 9.4, median C-reactive protein (CRP) of 6.6 g/dL, and median faecal calprotectin (FC) of 1778 mg/kg. At week 14, etrolizumab treatment was associated with clinical response in 50.8% of patients, remission in 12.3%, ES 1 in 23.9%, RB remission in 52.3%, and SF remission in 35.4%. 43.9% of patients had !1-point improvement from BL in the ES, and improved ES were associated with increased rates of RB and SF remission. Among patients with ES ¼ 0, 100% reported RB 1, and 90% reported SF 1 ( Table 1) . Patients who achieved SF remission, RB remission, or ES 1 also demonstrated 450% geometric mean reduction in CRP (BL ! 2.87 mg/L) and 470% geometric mean reduction in FC. Table 1 : Lower ES at week 14 was associated with higher SF and RB remission rates (N ¼ 130) Improvement in ES From BL (n ¼ 57)
No Improvement From BL (n ¼ 73)
Week 14
Conclusion: aTNF-experienced patients with moderate-severe UC and high disease burden treated with open-label etrolizumab for 14 weeks achieved clinically meaningful clinical response, remission, and endoscopic improvement. Patients who had a decline in ES ! 1 achieved higher rates of RB and SF remission and greater reductions in inflammatory biomarkers. Recruitment to HICKORY continues in a randomised, placebo-controlled induction cohort, and a randomised maintenance phase is also ongoing. Contact E-mail Address: wsandborn@ucsd.edu Introduction: Etrolizumab, a humanised anti-b7 monoclonal antibody currently undergoing Phase 3 evaluation in ulcerative colitis (UC) and Crohn's disease (CD), was well tolerated and efficacious in patients with moderate to severe UC in the Phase 2 trial EUCALYPTUS. BERGAMOT (NCT02394028), a Phase 3 study, was designed with 3 sequential induction cohorts and a single maintenance cohort to evaluate the safety and efficacy of etrolizumab in patients with moderate to severe CD. This abstract describes results for the exploratory induction cohort of 300 patients. Aims & Methods: In this multicentre, randomised, double-blind study, eligible patients with moderate to severe CD (confirmed at baseline with centrally read ileocolonoscopy) who were refractory or intolerant to anti-tumor necrosis factor agents (aTNFs), immunosuppressants, and/or corticosteroids were assigned in a 2:2:1 ratio to receive etrolizumab 105 mg subcutaneously every 4 weeks, etrolizumab 210 mg at weeks 0, 2, 4, 8, and 12, or placebo during a 14-week induction period. End point assessments included CDAI remission (CDAI 5 150), CDAI-100 response, CDAI-70 response, PRO2 remission (weighted combined score 11, based on patient report of liquid/very soft stool frequency [SF] and abdominal pain [AP]), symptomatic remission (unweighted SF 3 and AP 1), and endoscopic improvement (!50% reduction from baseline SES-CD using central reading) at week 14. Results: 300 patients (73% aTNF-experienced) with moderate to severe CD (mean CDAI [SD] , 315. 6 [60.0] ; mean SES-CD [SD], 14. 1 [7.3] ; median faecal calprotectin [range] , 918 [30-15451] mg/g; median C-reactive protein [range], 9.75 [0.2-148 .0] mg/L) received etrolizumab 105 mg (n ¼ 120), etrolizumab 210 mg (n ¼ 121), or placebo (n ¼ 59). Symptomatic remission (SF 3 and AP 1) was observed in a greater proportion of patients treated with etrolizumab 105 mg and 210 mg compared with placebo at weeks 6, 10, and 14 ( Table 1) . A greater proportion of patients achieved endoscopic improvement with etrolizumab 105 mg and 210 mg compared with placebo at week 14 ( Table 1) . CDAI remission was achieved at week 14 in 23. 3% (17.6, 30.2) of patients receiving etrolizumab 105 mg, 28.9% (22.7, 36.1) of those receiving 210 mg, and 16. 9% (10.4, 26.4 ) of those receiving placebo; PRO2 remission was achieved at week 14 in 28. 3% (22.1, 35.5), 28.9% (22.7, 36.1) , and 20. 3% (13.1, 30.2) of patients, respectively. Etrolizumab was well tolerated. The frequency of adverse events was comparable with placebo, and no deaths, anaphylaxis, or progressive multifocal leucoencephalopathy occurred. 11.9% (6.6, 20.5) 20.8% (15.4, 27.5) 24.8% (18.9, 31.8) Endoscopic improvement (!50% reduction from baseline SES-CD)
Week 14 3.4% (1.1, 9.7) 21. 0% (15.6, 27.8) 17.4% (12.4, 23.7) AP, abdominal pain; SES-CD, Simple Endoscopic Score for Crohn's Disease; SF, stool frequency.
Conclusion:
In this exploratory induction cohort, treatment with etrolizumab was well tolerated and resulted in clinically meaningful endoscopic improvement, with rapid symptomatic remission as early as week 6 that was sustained through week 14. These early results are indicative of the efficacy of etrolizumab in treating CD. Enrolment into subsequent induction cohorts and into the maintenance phase of BERGAMOT is ongoing.
blinded manner. Crohn's Disease Activity Index (CDAI)-70 response, clinical remission (CDAI score5150), Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and safety including immunogenicity were evaluated.
Results : Of 220 patients randomized, 180 patients completed Week 30 visit and  166 patients completed the study. CDAI-70 response and clinical remission rates  were similar between CT-P13 and INX up to Week 30. At Week 54, clinical remission as well as CDAI-70 response rates were maintained and similar in 4 treatment groups even after switching of study drug. Furthermore, SIBDQ score increased and was similar among 4 treatment groups up to Week 54 even following switching of study drug (Table 1) . One-year safety including adverse drug reactions, serious adverse events and infections was similar among all treatment groups and all safety profiles were also similar after Week 30 in maintenance and switching groups (Table 1) . At Week 30, only 1 infusion-related reaction (IRR) was reported to CT-P13 to INX group after switching of study drug and this patient was anti-drug antibody (ADA) positive at Week 30. No further IRR was reported for switching groups after Week 30. There were no clinically meaningful differences in immunogenicity results throughout the study period among treatment groups up to Week 54. 
Week 6 (IBD) . V565 is a novel oral domain antibody (Vorabody) to TNF engineered to be resistant to intestinal proteases and formulated to be delivered effectively to inflammation in the ileum and colon. It is being developed as a potential oral treatment for IBD. It has previously been shown to suppress phosphorylation of multiple receptor tyrosine kinases and cytoplasmic signalling proteins, and inhibit the release of inflammatory cytokines following culture with biopsies taken from patients with active CD (Crowe et al. 18th International Congress of Mucosal Immunology, July 19-22 2017, Washington DC, USA). In an earlier clinical study V565 was safe and well tolerated after high single and multiple doses given to healthy volunteers and patient volunteers with Crohn's disease. In addition, after a single oral dose, high concentrations of active compound were detected in the ileal fluid and faeces of human volunteers, and it was also detected in the urine of a patient with Crohn's disease indicating passage through the lamina propria.
Aims & Methods: The present study was designed to translate the preclinical antiinflammatory findings to the clinical situation and demonstrate that V565 exerts a beneficial effect on inflammatory processes following oral dosing for seven days to patients with Ulcerative Colitis (UC) . In this open label study patients with a Mayo score of 3-10, including an endoscopy score of at least 1 had a pre-treatment sigmoidoscopy with biopsies, followed by 7 days of oral dosing with 555 mg tid V565. After completion of dosing a further sigmoidoscopy with biopsies was performed. The biopsies were analysed for presence of V565 in the mucosa using immunohistochemistry and reduction in phosphorylation of a panel of receptor tyrosine kinases and signalling molecules using PathScan RTK signalling arrays.
Results: Four subjects have completed the study. V565 was demonstrated in the lamina propria and co-localisation with CD14 indicated binding to mTNF on macrophages. The reduction in overall protein phosphorylation following treatment was approximately 50% in each patient. This indicates a reduction in activation of kinase signalling, and is similar to the reduction seen in Crohn's disease and UC ex vivo biopsy cultures with infliximab at a concentration of 10 mg/ml (67 nM) in an earlier study. Conclusion: V565, an oral domain antibody to TNF engineered to be resistant to intestinal proteases, was demonstrated co-located with CD14 macrophages in the intestinal lamina propria and resulted in inhibition of mucosal inflammatory processes after seven days oral dosing to patients with ulcerative colitis. The reduction in overall phosphorylation after oral dosing in this study was comparable to that seen in an earlier experiment with a biopsy culture with infliximab at a concentration of 10 mg/ml, a serum concentration associated with mucosal healing (Ungar et al., 2016) . This is the first demonstration of biological effect in patients following oral dosing of a domain antibody to TNF engineered to be resistant to intestinal proteases and with minimal systemic exposure. The data provide encouragement that V565 has the potential to be a safe and effective treatment option in IBD. Introduction: TNF-inhibitors have improved treatment of Crohn's disease (CD), ulcerative colitis (UC), rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and chronic plaque psoriasis. The NOR-SWITCH 52-week, double blind, noninferiority trial showed that switching from originator (RemicadeÕ, IFX) to biosimilar (RemsimaÕ, CT-P13) infliximab was not inferior to continued treatment with IFX regarding efficacy, safety and immunogenicity. 1 Though explorative subgroup analyses in CD demonstrated an estimated difference close to the non-inferiority margin for CT-P13, the trial was not powered for demonstrating non-inferiority in the individual diagnoses. 1 Aims & Methods: In the 26-week open label NOR-SWITCH EXTENSION trial treatment efficacy, safety and immunogenicity were assessed in patients on CT-P13 throughout the 78-week study period (maintenance group) compared to patients switched from IFX to CT-P13 at week 52 (switch group). The primary endpoint was disease worsening during follow-up according to disease-specific indices. Explorative subgroup analyses were performed to examine disease worsening within each of the six diagnoses. Results: In total, 380 of 451 patients in the main trial entered the extension phase (Full Analysis Set). Overall disease worsening occurred in 16.8% (32/190) and 11.6% (20/173) in the maintenance and switch arms, respectively, and the 95% confidence interval (CI) of the adjusted difference was within the pre-specified 15% non-inferiority margin (À5.9%; 95% CI À12.9,1.1) (Per Protocol Set, PPS). The incidence of adverse events and anti-drug antibodies (ADAb) were comparable between arms. In CD, disease worsening occurred in 20.6% and 13.1% (À7.9%; 95% CI À21, 5.2) and in UC in 15.4% and 2.9% (À12.4%; 95% CI À25, 0.1) of patients in the maintenance and switch group, respectively (PPS) (table). These results were within the non-inferiority margin. The baseline characteristics in CD and UC when entering the extension trial at week 52 showed no difference between arms regarding age, gender, previous biologic therapy, use of immunosuppressants, trough drug levels, disease duration, extension, behaviour and activity (Harvey-Bradshaw Index (HBI) and Partial Mayo Score (PMS)), bowel surgery, smoking, CRP, faecal calprotectin, and EQ-5D. Changes in disease measures from baseline to study end in CD and UC, respectively, showed similarity between treatment arms regarding HBI, PMS, HBI and PMS remission, CRP, faecal calprotectin and Patient's and Physician's global assessment of disease activity (PPS)( Results: IV UST induced significant improvement in all 3 components within the first 2 wks, with AP first significantly better than PBO on d2 for both UST doses, and consistently significantly better than PBO from d6 through d14 for 6 mg/kg and from d8 through d14 for 130 mg. Mean improvement in SF was first significantly better than PBO on d7 for UST both doses, while this occurred on d8 for WB. Week 1 and 2 SF þ AP with CDAI weighting was significantly improved for both UST doses vs PBO at d7 and d14, & SF þ AP added with equal 1:1 weight was significantly improved for both UST doses at d14. 29.3% of 6 mg/kg & 31.4% of 130 mg groups attained !50 pt improvement in CDAI solely based on SF&AP components over the second week vs 18.8% in the PBO group (p 5 0.05 and p 5 0.01, respectively). Conclusion: Even in the refractory CD population of previous anti-TNF failures in UNITI-1, symptom relief based on individual pt-reported CDAI components began to show significant improvement as early as 1 day post UST infusion, and was seen consistently among all 3 components by d8 with both IV UST doses, confirmed by consistent PRO2 benefit in the second week. These findings support previously reported significant early efficacy seen at the post-baseline (Wk3) . We observed heterogeneity between men and women for CRC incidence (P ¼ 0.004) and mortality (P ¼ 0.014). In men, CRC incidence was reduced by 65.5 per 100,000 personyears (95% CI 80.8 to 36.9 reduction), and CRC mortality by 23.2 per 100,000 person-years (95% CI 32.8 to 8.7 reduction) in the screening group versus the control group. In women, screening did not reduce CRC incidence (13.5 reduction per 100,000 person-years; 95% CI 35.4 reduction to 8.5 increase) or mortality (0.43 increase per 100,000 person-years; 95% CI 11.7 reduction to 12.6 increase). Conclusion: Once-only sigmoidoscopy screening reduces colorectal cancer incidence and mortality for up to 17 years in men, but we found little or no apparent effect in women. Introduction: Current guidelines for the management of patients with metastatic colorectal cancer (mCRC) advise a bimonthly treatment response evaluation 1 . However, growing evidence demonstrated that early tumour shrinkage is associated with long-term outcome 2, 3 . Cell-free circulating DNA (cfDNA) assessment offers a highly specific and minimally invasive method amenable on regular basis to patients, but is currently impaired by the lack of consensus markers 4 . Early alterations in methylation patterns are highly prevalent and limited to specific regions of the genome, allowing for a universal assay design compatible for population studies. Aims & Methods: We aimed to identify an optimal panel of cancer specific biomarkers for the purpose of monitoring therapeutic outcome in cfDNA in mCRC patients. Comparison of genome-wide DNA methylation profiles of a collection of 149 CRC cell lines with normal mucosa and blood cells identified five genes (EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC) to be used as universal liquid biopsy assay for mCRC. Markers were validated in silico using methylome data from CRC specimens. Digital PCR-based assays were then designed and performed in tissue (N ¼ 112) and cfDNA samples from mCRC patients (N ¼ 182) and self-declared healthy donors (N ¼ 50). Retrospective longitudinal assessment of the panel was performed and compared to current gold standards (imaging, CEA). Results: Average methylation (and range) was 2.3% [0. 2-8.4] and 55.2% [20. .9] for normal tissues and for macro-dissected matched tumour tissues respectively (p 5 0.001). Using cfDNA individual markers easily stratified self-declared healthy donor from mCRC patients samples (average specificity: 0.96; average specificity: 0.69). Male gender was significantly associated with lower methylation values (p ¼ 0.023), while the presence of unresected primary tumour (p ¼ 0.002), bulky disease (defined as massive tumour involvement of 450% of liver or lungs; p ¼ 0.012) or multiple metastatic lesions (p ¼ 0.023) were significantly associated with higher methylation values, while CEA levels were less informative. Longitudinal assessment in cfDNA of patients treated with chemotherapy (N ¼ 8) recapitulated tumor burden changes as assessed by imaging, with a decrease preceding partial response, while an increase in methylation anticipated progression. For cases with known mutations in the tumor tissue, KRAS or BRAF mutant levels in cfDNA were consistent with methylation values. In patients treated with the EGFR inhibitor panitumumab (N ¼ 5), disease progression was associated to an increase in methylation levels and the emergence of resistance causative alterations (acquired RAS mutations or MET gene amplification). Finally, drop in methylation of markers in cfDNA correlated with objective tumor response (as assessed by conventional radiological methods; PPV ¼ 0.82; NPV ¼ 0.79, p ¼ 0.0048) and progression-free survival (p ¼ 0.042, HR relapse ¼ 0.48 [0.17-0.88]) in 29 mCRC patients enrolled in the TEMECT clinical trial (Temozolomide). Conclusion: This panel of methylated markers was able to monitor tumour burden in colorectal cancer patients treated with different conventional treatment regimens, including chemotherapy, anti-angiogenic agents and targeted agents. Liquid biopsy based on methylated markers could be coupled with imaging to improve timely therapeutic changes. This approach could also be useful for early pharmacodynamic assessments in clinical trials in particular for those using drugs for which no reliable biomarker of response are available (e.g.: regorafenib) 5 Contact E-mail Address: r.rameshshanker@nhs.net Introduction: Adenoma detection rates at colonoscopy are directly linked to subsequent risk of post colonoscopy cancer. One of the main reason for missing adenomas is poor visualisation of proximal folds and flexures during standard colonoscopy. Disposable distal attachments such as the cap and the Endocuff vision device have been reported to improve adenoma detection compared to standard colonoscopy. There are however no comparative randomised trials of these two devices Aims & Methods: Aim The primary aim of this study was to compare the adenoma miss rate between Endocuff-assisted colonoscopy (EAC) and Cap-assisted colonoscopy (CAC). Methods All Patients referred for a colonoscopy via symptomatic services were invited to participate in the study. This is a randomised, single centre, tandem colonoscopy trial with both examinations performed by the same endoscopist, on the same day first with Endocuff Vision followed by cap or vice-versa. The study was approved by local research ethics committee and registered on a trial database(ISRCTN58994883) All procedures were performed by Gastroenterology Fellows who had performed more than 1500 colonoscopies each. Results: A total of 154 patients were recruited. 78 of them had CAC as their first procedure. The mean age of participants was 61 years (male: female ratio was 1:1). The main findings of the study were shown in table 1. The polyp miss rate was significantly lower in EAC (8.4%) when compared with CAC (26.1%, p 5 0.001). Adenoma miss rate was significantly lower for EAC (EAC vs CAC, 6%, vs 19%, p ¼ 0.002). Miss rate for diminutive adenomas (56 mm) were significantly lower in EAC group (1.8% vs 19.6%, p 5 0.001), however, there was no significant differences in the miss rates for small (6-10 mm) (3.7% vs 2.9%, p ¼ 0.69) or adenomas larger than 10 mm (2.6% vs 1.6%, p ¼ 0.98). There was no significant difference in cancer, advanced adenoma or serrated polyps miss rate. The mean number of adenomas per procedure was significantly higher in EAC group when compared to CAC (1.5 vs 0.8, p 5 0.001). Caecal intubation time was significantly shorter in the EAC group than CAC group (median 6 vs 7 mins, p ¼ 0.01) Conversely, withdrawal time (median 10 vs 8 mins, p ¼ 0.01) was significantly longer in the EAC group. This difference was probably due to more polyps detected and resected in the EAC group. While introducing the colonoscope via the anus the discomfort score was higher in EAC (55% vs 10%, p 5 0.001). However, the majority reported only mild discomfort During the first procedure, Endocuff was removed in 5/76(6.6%) patients' due to difficulties to pass the Endocuff through a fixed or narrowed sigmoid colon. There were no difficulties to negotiate the sigmoid colon when the cap was used. There were no other colonoscopy related complications reported during the procedure. To assess the diagnostic accuracy of the second generation colon capsule endoscopy (CCE-2) among screenees with a positive faecal immunochemical tests (FIT) result in the context of population based programmes for colorectal cancer (CRC) screening. We targeted for enrolment subjects aged 50 to 69, with a positive FIT result, examined in 4 population based programmes in Italy and Spain, using the same test (Eiken co.) and adopting the same positivity cut-off (20 mgr. Hb/gr. faeces). Screenees meeting the inclusion criteria for the study (no swallowing disorders, or chronic disease which might increase the risk of preparation side-effects, or allergy to iodine) were invited to participate.
Volunteers were asked to perform the CCE-2 examination, followed by the colonoscopy (TC). The TC was performed the same day as the CCE-2, if the capsule was excreted before 2 p.m., while in the other cases the screenee was given an additional bowel preparation and the TC was scheduled for the following morning. Bowel preparation protocol for CCE-2 included a high-volume splitted PEG-based regimen and NaP and Gastographin as boosters. The CCE-2 film was read by an experienced endoscopist, blinded to the results of the TC examination. A second TC was planned, if the CCE-2 detected a polyp 49 mm not detected by the TC. All readers had previous experience with the colon and small bowel capsule and they underwent a one day training course before starting the study. Only two endoscopists in each centre were involved in the study to minimize inter-individual variability. The main outcomes were sensitivity and specificity of CCE-2 for advanced neoplasia (AN: advanced adenoma þ CRC), when using different size thresholds for TC referral (i.e. 45 or 49 mm polyp Aims & Methods: Aim: To provide proof of concept for effective prepless CRC screening. Herein, the efficacy for polyp detection and safety is reported. Methods: In a prospective multi-center comparative study, all patients underwent the capsule procedure and FIT (OC-Light, Eiken, Japan) with subsequent colonoscopy as the gold reference. The population consisted of average risk subjects that were enriched with subjects with known non-resected polyps (previous colonoscopies or CT colonography). After swallowing the capsule, they swallowed iodine-based contrast agent (Omnipaque 350, GE Healthcare, US) necessary for generating images (15 cc TID). A tablespoon of fiber was given with the iodine to improved capsule motility. The tracking and control unit was subsequently attached to the patients' back. This unit commands the capsule to scan and collects imaging and position data. Patients continued their normal daily routine and reported their comfort level. Capsule data was analyzed post-hoc for the occurrence of colonic polyps by a trained physician and imaging engineers. The team was blinded to the results of FIT and colonoscopy. Sensitivity and specificity of the capsule findings were calculated with reference to colonoscopy.
Results were analyzed as a function of the percent of colon length effectively covered by the scanning capsule. Results: Sixty six patients (ages 37-79 yr, 40 male) were enrolled. Forty three had un-resected polyps (410 mm) and 23 were average risk. Forty five procedures were analyzed. Dropouts included technical failures (13) and physiological/anatomical outliers (8). Average transit time was 52 AE 32 hours. All patients continued their daily routine with normal diet. No device-related serious adverse events (SAE) occurred. Infrequent, anticipated AE included soft stool, mild abdominal pain, headache and rash under the back sticker. All AE resolved without intervention within a few hours. Average calculated total body X-ray dose exposure was 50 mSv (abdominal CT scan dose exposure is 8-15X10 3 mSv). Two capsules were retained and needed to be retrieved by colonoscopy, despite lack of symptoms. One was retained in the appendiceal orifice, while the other was removed at the patient's request concomitantly with polypectomy. Sensitivity and specificity of capsule findings as function of the coverage of colonic length were as follows: Sensitivity of FIT alone was 37% in all analyzed procedures, and p-value was calculated relative to this. The correlation between the capsule scan coverage length and sensitivity (R^2) was 0.98. Conclusion: Prepless colonic screening, using an X-ray imaging capsule, is feasible and safe with high acceptance and no side effects. Capsules were highly specific. Those covering the majority of the colon showed excellent sensitivity in detecting polyps. Future improvements in colonic coverage are anticipated to provide even higher sensitivity. Contact E-mail Address: markus@peck.at Introduction: Thrombocytopenia (TCP) is a common complication of chronic liver disease (CLD), which may cause delay or avoidance of invasive procedures. Lusutrombopag (LUSU) is an agonist of human thrombopoietin receptor. Here we report results from a Phase 3 study (L-PLUS 2) evaluating LUSU for treatment of TCP in patients with CLD who were undergoing non-emergency invasive procedures.
Aims & Methods: Key eligibility criteria included !18 years old, diagnosis of CLD, baseline platelet count 550 Â 109/L, Child-Pugh Class A or B, and planned non-emergency invasive procedure. Patients were randomized 1:1 to receive oral LUSU 3 mg once daily or placebo for up to 7 days. Invasive procedures were performed between Day 9 and 14. Platelet transfusion was mandated if pre-procedure platelet count was 550 Â 109/L. Primary efficacy endpoint was proportion of patients who required no platelet transfusion prior to the procedure and no rescue therapy for bleeding up to 7 days post-procedure. Safety assessment included adverse events and imaging for detection of portal vein thrombosis (PVT). Results: 215 patients were randomized at study sites in 22 countries (ITT population, LUSU 108, placebo 107). Baseline patient characteristics were similar between two groups. The most common invasive procedures included endoscopic variceal ligation (28%), endoscopy with or without polypectomy/biopsy (27%), dental extraction (11%), and TACE (9% (20, 40, 80, and 160 mg) was conducted in healthy subjects. Twelve subjects for each dose group received oral dose of DWP14012 or esomeprazole (40 mg, active comparator) or placebo in a ratio of 8:2:2 for 7 days. PK of DWP14012 was evaluated up to 24 h after single dose (day 1) and after steady-state (day 7). PD of DWP14012 was evaluated through 24-h gastric pH monitoring at baseline (day -1), day 1 and day 7. Tolerability evaluation including laboratory tests was conducted throughout the study.
Results: A total of 49 subjects were enrolled and 48 subjects were completed the study. Following multiple oral administration of DWP14012, the maximum plasma concentration was observed 1.5 to 5 hours after dose and showed firstorder elimination profile with a mean half-life of 7.51 to 9.52 hours. The DWP14012 did not significantly accumulate in the plasma by once daily multiple administrations. The plasma concentration of DWP14012 increased dose proportional manner. The increased gastric acid suppression according to dose of DWP14012 and clear exposure-response relationship were observed; the percentages of time pH above 4.0 at day 7 were 38. 3 %, 55.7 %, 87.4 %, and 99.2 % in DWP14012 20, 40, 80 , and 160 mg dose group, respectively, whereas, the values were 11.2 % and 59.4 % in placebo and esomeprazole 40 mg dose group; the mean pH at day 7 were 3.4, 4.2, 5.7, and 6.5 in DWP14012 dose groups, respectively, whereas, the value was 2.1 and 4.3 in placebo and esomeprazole group. The gastric pH parameters observed in the subjects who received DWP14012 40 mg were similar to those of who received esomeprazole 40 mg. DWP14012 showed rapid and sustained suppression of gastric acid secretion during 24 hours after dosing. There were no serious adverse events and no clinically significant changes in tolerability parameters. Conclusion: DWP14012 was well tolerated after 7 days of oral administrations at doses up to 160 mg in healthy subjects, and the PK and PD properties evaluated in the first time in human represented the rapid and long-lasting gastric acid suppression effect of DWP14012. These results suggested that DWP14012 may be effective for the treatment of acid-related diseases. [1] [2] [3] [4] . A new portable battery-powered system (cryoballoon focal ablation system (CbFAS)) freezes esophageal mucosa with nitrous oxide [5] [6] . This is the first clinical trial evaluating the safety and efficacy of the CbFAS for curative treatment of Barrett's neoplasia.
Aims & Methods: AIM: To determine the safety and efficacy of nitrous oxide cryoballoon ablation for eradication of neoplastic Barrett's esophagus. METHODS: In a multicenter, prospective single-arm clinical trial, consecutive BE patients with confirmed neoplasia (LGD, HGD, and/or T1aECA) without prior ablation therapy (''treatment-naı¨ve'') or persistent/recurrent disease despite prior ablative therapies (''previously ablated'') were treated with a cryogen dose of 10 seconds per site (video). EMR was performed for lesions at least 8 weeks prior to cryoablation. Patients were included if there was biopsy-proven neoplastic BE 4 1 cm, with no upper limit on length. Patients were excluded if they had an esophageal mass, advanced or metastatic cancer, prior esophageal resection, esophageal varices, or uncontrolled coagulopathy. Treatments were repeated every 10-12 weeks until complete eradication, maximum of 5. Primary outcomes were complete eradication of all dysplasia (CR-D) and intestinal metaplasia (CR-IM) at 1 year (intention-to-treat analysis). Patients who were treated with alternative therapies (ablation or surgery) or developed more advanced neoplasia grade were considered failures. Results: 42 consecutive patients were enrolled, 2 excluded (no dysplasia on review). 40 patients (21 treatment-naı¨ve, 19 previously ablated, were treated. Mean Prague C 1.7 cm, mean Prague M 4.1 cm, with low grade dysplasia (LGD n ¼ 13), high grade dysplasia (HGD n ¼ 23) or ImCA(n ¼ 4). 34(85%) had a maximum BE length 58 cm, 6(15%) with !8 cm. All but 1 of 114 procedures were successful. Median procedure time was 32 minutes (IQ range 24-35). Mean number of ablation procedures for all patients was 2.8, range 1-5. Overall, 1 year CR-D and CR-IM rates were 95% and 88%, respectively, with no significant difference in those with or without prior ablation. CR-D rate was significantly lower (67%) in those with ultra-long BE 48 cm compared to those with 58 cm (100%, p ¼ 0.02). One patient in the former group had a 3 mm residual ImCA in a stricture and opted for surgery, while another with BE HGD in post RFA stricture had rescue APC. Median immediate post-ablation pain score (Likert scale 1-10) was 1 (IQR 0-2.5) but rapidly decreased to 0 by 24 hours (IQR 0-2). Two (5%) patients required narcotics for post-ablation pain after day 1. 4 patients (10%) developed mild Grade 1-2 dysphagia from inflammatory stenosis requiring dilation. One patient on aspirin developed upper GI bleeding 2 weeks after treatment, not requiring therapy. Conclusion: Multifocal nitrous oxide cryotherapy using a CbFAS is a promising, highly effective, and safe endoscopic treatment for primary or rescue therapy of BE-associated neoplasia. Device improvements are ongoing and larger multicenter comparative clinical trials are planned to assess long-term safety and efficacy. 
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Contact E-mail Address: jeremiejacques@gmail.com Introduction: Gastroparesis is a functionnal disorder defined by delayed gastric emptying without mechanical obstruction and cardinal symptoms (nausea, vomiting, early satiety). It's prevalence is high around 3% in USA. Treatment of gastroparesis is based on specific diet (frequent small meals with low fat and low fiber) and prokinetics drugs. However these drugs are concerned by a lot of cardiac side effect, and a lot of patients escape because of a tachyphylaxy effect. In case of failure of these treatments, there is no validated therapeutic alternative. POP has recently been reported in retrospective series 1-5 as a promising endoscopic procedure to treat refractory gastroparetic patients. We report the first prospective study evaluating feasibility, safety and efficacy of POP for refractory gastroparetic patients. Aims & Methods: 20 refractory gastroparetic patients (10 diabetic and 10 nondiabetic) has been prospectively included in this pilot trial (NCT02779920). They were treated by POP after measurement of pyloric dysfunction using Endoflip. Clinical response was evaluated by GCSI, quality of life by Pagy-Qol and GIQLI scores, at 1 and 3 months. Evolution of gastric emptying was analysed thanks to a 4 hours gastric scintigraphy at 3 months according to recommendations of American society of nuclear medicine. All procedures were performed by two operators with large expertise in Endoscopic submucosal dissection. Results: Feasibility was 100%. Median duration of procedure was 56.5 min (48. 5-67.0) . No severe adverse events linked to the procedure were recorded. POP significatively improved symptoms (Figure 1 ) (GCSI:1,3 vs 3,5 p 5 0,0001), improve quality of life(PAGY-QoL: 4,1 vs 3 p 5 0,0001; GIQLI: 97 vs 63 p 5 0,001) and gastric emptying ( Figure 2 ) (T1/2:100 min vs 345 min p ¼ 0,0007; %H2: 56% vs 81,5% p 5 0,001; %H4 15% vs 57,5% p ¼ 0,0025) at 3 months. All individual cardinal symptoms were significatively improved (Figure 3) . A threshold of distensibility at 9.2 mm 2 /mmHg with a 50 cc inflated Endoflip predict clinical success of POP with a specifity of 100%, a sensibility of 72.2% (p ¼ 0,04; IC 95%:0,509-0,935; AUC:0,722). Conclusion: Discussion: POP is feasible and safe when perfomed by operators with expertise in ESD. POP clearly accelerates gastric-emptying. It seems to improved symptoms and quality of life of severe refractory gastroparesis patients but prospective blinded randomized trial is needed for this subjective endpoint. Pyloric function evaluation by Endoflip seems to be very promising to best identify gastroparetics patients in which pylorospasm is involved(Distensibility 59,2 mm 2 /mmHg). Conclusion: We confirm in this first prospective study feasibility, safety and efficiency of POP for severe refractory gastroparesis. POP accelerate gastric emptying in gastroparetic patients and improve all individual cardinal symptoms at 3 months in particular in patients with a low pyloric ditensibility measured by Endoflip. A long term follow-up, blinded randomized trial, and large multicentre cohorts using validated tools to evaluate function are urgently needed to confirm these promising results and to best identify the adequate place of POP in the armamentarium of therapeutic procedures for refractory gastroparesis. Disclosure of Interest: All authors have declared no conflicts of interest.
